home / stock / supn / supn quote
Last: | $25.77 |
---|---|
Change Percent: | 0.23% |
Open: | $26.49 |
Close: | $25.77 |
High: | $26.49 |
Low: | $25.66 |
Volume: | 270,159 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$25.77 | $26.49 | $25.77 | $26.49 | $25.66 | 270,159 | 07-02-2024 |
$26.55 | $26.85 | $26.55 | $27.285 | $26.33 | 336,080 | 07-01-2024 |
$26.75 | $27.02 | $26.75 | $27.55 | $26.56 | 2,640,715 | 06-28-2024 |
$26.87 | $26.78 | $26.87 | $26.905 | $26.17 | 480,397 | 06-27-2024 |
$26.72 | $26.31 | $26.72 | $26.96 | $26.1716 | 441,251 | 06-26-2024 |
$26.51 | $26.88 | $26.51 | $27.04 | $26.43 | 422,574 | 06-25-2024 |
$26.91 | $27.08 | $26.91 | $27.58 | $26.86 | 443,179 | 06-24-2024 |
$27.04 | $26.86 | $27.04 | $27.38 | $26.58 | 3,528,611 | 06-21-2024 |
$26.8 | $26.49 | $26.8 | $26.9 | $26.15 | 507,820 | 06-20-2024 |
$26.66 | $25.98 | $26.66 | $26.88 | $25.86 | 535,794 | 06-19-2024 |
$26.66 | $25.98 | $26.66 | $26.88 | $25.86 | 535,794 | 06-18-2024 |
$25.99 | $25.82 | $25.99 | $26.52 | $25.82 | 432,597 | 06-17-2024 |
$25.99 | $26.31 | $25.99 | $26.59 | $25.53 | 413,875 | 06-14-2024 |
$26.56 | $26.91 | $26.56 | $27.08 | $26.37 | 439,915 | 06-13-2024 |
$27.08 | $26.77 | $27.08 | $27.46 | $26.235 | 601,939 | 06-12-2024 |
$26.2 | $26.03 | $26.2 | $26.31 | $25.64 | 395,508 | 06-11-2024 |
$26.19 | $25.99 | $26.19 | $26.31 | $25.65 | 746,792 | 06-10-2024 |
$26.26 | $26.96 | $26.26 | $27.1 | $25.9 | 871,087 | 06-07-2024 |
$27.15 | $27.55 | $27.15 | $28.33 | $26.35 | 762,729 | 06-06-2024 |
$27.54 | $27.98 | $27.54 | $28 | $27.18 | 486,947 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals Inc. Company Name:
SUPN Stock Symbol:
NASDAQ Market:
Supernus Pharmaceuticals Inc. Website:
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supern...
2024-05-24 08:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SPN-817 is a novel, first-in-class highly selective acetylcholinesterase (AChE) inhibitor for epilepsy Company to host webcast today at 4:30 p.m. ET to discuss the interim data ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharm...